Cullinan Therapeutics, Inc. (CGEM)
- Previous Close
19.25 - Open
19.27 - Bid 18.12 x 200
- Ask 25.44 x 200
- Day's Range
19.27 - 25.72 - 52 Week Range
7.64 - 25.72 - Volume
4,737,577 - Avg. Volume
638,949 - Market Cap (intraday)
1.09B - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-3.69 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
28.00
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
cullinantherapeutics.comRecent News: CGEM
Performance Overview: CGEM
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CGEM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CGEM
Valuation Measures
Market Cap
1.09B
Enterprise Value
626.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.29
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.80%
Return on Equity (ttm)
-31.37%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-153.16M
Diluted EPS (ttm)
-3.69
Balance Sheet and Cash Flow
Total Cash (mrq)
467.07M
Total Debt/Equity (mrq)
0.79%
Levered Free Cash Flow (ttm)
-88.76M
Research Analysis: CGEM
Company Insights: CGEM
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: CGEM
Daily – Vickers Top Buyers & Sellers for 06/24/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 05/17/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/07/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.